Lung Carcinoma (NSCLC) Profile Test
50+ booked in last 3 daysOverview
The "Lung Carcinoma (NSCLC) Profile" is a comprehensive test used to evaluate specific markers and genetic alterations in non-small cell lung carcinoma (NSCLC). It involves the analysis of lung tissue obtained through a tru-cut biopsy and includes the following components: Reflex Immunohistochemistry (IHC): Immunohistochemistry is a technique that uses antibodies to detect specific proteins in tumor tissue. In this profile, reflex IHC is used to assess the presence of two critical biomarkers: EGFR & ALK. EGFR (Epidermal Growth Factor Receptor) Mutation Detection: The test specifically detects mutations in two common EGFR exons - Exon 19 deletion and Exon 21 L858R. EGFR mutations are important molecular markers in NSCLC and can guide treatment decisions, as certain targeted therapies are available for patients with EGFR-mutated tumors. ALK (Anaplastic Lymphoma Kinase) IHC: ALK rearrangements are another genetic alteration found in a subset of NSCLC patients. ALK IHC is used as a screening tool to identify tumors with ALK rearrangements, and if positive, further confirmatory tests are conducted. The results of this profile provide valuable information to guide personalized treatment strategies for patients with NSCLC. Based on the detected biomarkers, targeted therapies can be considered to improve treatment outcomes and potentially avoid unnecessary exposure to ineffective treatments. Additionally, the profile aids in disease prognosis and monitoring to assess treatment response over time.
Lung Carcinoma (NSCLC) Profile Test Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the Lung Carcinoma (NSCLC) Profile Test with a clear pricing structure.
The Lung Carcinoma (NSCLC) Profile Test Price in Mumbai is ₹ 12,190 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
The Lung Carcinoma Profile measures multiple attributes related to lung carcinoma, including the following: • Genetic mutations such as EGFR gene alterations in Exon 19 deletion and Exon 21-L858R • Protein expression of ALK that helps identify anaplastic lymphoma kinase rearrangements • Histopathological features that provide information about the type and characteristics of the lung carcinoma
• To make an accurate diagnosis and subtyping of lung carcinoma • To identify specific genetic mutations and protein expressions that can guide targeted therapy decisions • To assess the prognosis and predict treatment response for non-small cell lung cancer (NSCLC) patients
The Lung Carcinoma Profile is recommended when: • there is a suspicion or diagnosis of lung carcinoma, especially non-small cell lung cancer, • determining the genetic mutations and protein expressions that may influence treatment options, or • evaluating treatment effectiveness or monitoring disease progression in NSCLC patients.
Abnormal results from the Lung Carcinoma Profile may indicate • specific genetic mutations or protein expressions associated with non-small cell lung cancer, • potential eligibility for targeted therapy or immunotherapy options, or • the need for further diagnostic tests or additional treatment considerations.
A tissue sample (FFPE block) obtained from a lung biopsy will be analysed. The sample will undergo PCR, FISH, Sanger sequencing, and IHC methods.
• Provide relevant clinical diagnosis, histopathology report, and any previous imaging or genetic testing reports related to lung carcinoma for accurate interpretation of results. • Inform your doctor if you have any specific requirements.
• Molecular testing for other genetic alterations like KRAS, BRAF, or ROS1 mutations • Blood tests for specific tumour markers like CEA (Carcinoembryonic Antigen) and CA 19-9
ALK by IHC for NSCLC
Non-small cell lung cancer is a type of lung cancer that accounts for around 85% of all lung cancer cases. It includes different subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype has distinct characteristics and treatment approaches.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.